RIZATRIPTAN BENZOATE Drug Patent Profile
✉ Email this page to a colleague
When do Rizatriptan Benzoate patents expire, and what generic alternatives are available?
Rizatriptan Benzoate is a drug marketed by Apotex Inc, Aurobindo Pharma Ltd, Glenmark Pharms Ltd, Jubilant Generics, Macleods Pharms Ltd, Natco Pharma Ltd, Norvium Bioscience, Panacea, Sandoz, Unichem, Alkem Labs Ltd, Avet Lifesciences, Chartwell Rx, Creekwood Pharms, Invagen Pharms, Mylan Pharms Inc, and Teva Pharms. and is included in twenty-five NDAs.
The generic ingredient in RIZATRIPTAN BENZOATE is rizatriptan benzoate. There are twenty-two drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the rizatriptan benzoate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Rizatriptan Benzoate
A generic version of RIZATRIPTAN BENZOATE was approved as rizatriptan benzoate by AUROBINDO PHARMA LTD on December 31st, 2012.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RIZATRIPTAN BENZOATE?
- What are the global sales for RIZATRIPTAN BENZOATE?
- What is Average Wholesale Price for RIZATRIPTAN BENZOATE?
Summary for RIZATRIPTAN BENZOATE
See drug prices for RIZATRIPTAN BENZOATE
Recent Clinical Trials for RIZATRIPTAN BENZOATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Merck Sharp & Dohme Corp. | Phase 3 |
Pharmacology for RIZATRIPTAN BENZOATE
| Drug Class | Serotonin-1b and Serotonin-1d Receptor Agonist |
| Mechanism of Action | Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for RIZATRIPTAN BENZOATE
Paragraph IV (Patent) Challenges for RIZATRIPTAN BENZOATE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| MAXALT-MLT | Orally Disintegrating Tablets | rizatriptan benzoate | 5 mg and 10 mg | 020865 | 1 | 2006-02-17 |
| MAXALT | Tablets | rizatriptan benzoate | 5 mg and 10 mg | 020864 | 1 | 2004-09-02 |
US Patents and Regulatory Information for RIZATRIPTAN BENZOATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan Pharms Inc | RIZATRIPTAN BENZOATE | rizatriptan benzoate | TABLET;ORAL | 201993-001 | Dec 31, 2012 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Creekwood Pharms | RIZATRIPTAN BENZOATE | rizatriptan benzoate | TABLET;ORAL | 202047-002 | Dec 31, 2012 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Unichem | RIZATRIPTAN BENZOATE | rizatriptan benzoate | TABLET;ORAL | 207836-001 | Mar 7, 2017 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sandoz | RIZATRIPTAN BENZOATE | rizatriptan benzoate | TABLET;ORAL | 079230-001 | Dec 31, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Unichem | RIZATRIPTAN BENZOATE | rizatriptan benzoate | TABLET;ORAL | 207836-002 | Mar 7, 2017 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Avet Lifesciences | RIZATRIPTAN BENZOATE | rizatriptan benzoate | TABLET;ORAL | 204090-002 | Nov 26, 2013 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Glenmark Pharms Ltd | RIZATRIPTAN BENZOATE | rizatriptan benzoate | TABLET;ORAL | 201967-001 | Dec 31, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
